Cardiology / Primary Care

Effective PCSK9 Inhibitor Therapy Starts With You: Overcoming Barriers to Patient Access

CME: 0.75

April 12, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This activity has been designed to meet the educational needs of primary care physicians and cardiologists.

Learning Objectives

After participating in the activity, learners should be better able to:

  • APPLY knowledge of PCSK9 inhibitor mechanism of action, efficacy outcomes, safety profiles, and prescribing information into clinical practice
  • EXPLAIN the possible mechanisms by which PCSK9 inhibitors could potentially mitigate morbidity and mortality outcomes associated with COVID-19
  • REVIEW barriers that inhibit patient access to PCSK9 inhibitors
  • SUMMARIZE strategies to improve patient access to PCSK9 inhibitors and ensure adherence and persistence to therapy

Post a comment to this article